-
Lisinopril Dihydrate in ACE Inhibitor Research
2026-09-24
Use Lisinopril dihydrate to probe ACE-dependent signaling in hypertension, cardiac, and renal research—with assay controls that help separate ACE inhibition from other peptidase effects. This practical guide covers solution preparation, experimental workflows, disease-model readouts, and troubleshooting, while distinguishing product specifications from suggested starting conditions.
-
Angiotensin 1/2 (1-6): Designing Better Binding Assays
2026-09-24
Angiotensin 1/2 (1-6), the Asp-Arg-Val-Tyr-Ile-His hexapeptide, offers a useful probe for studying how angiotensin fragments influence molecular binding. This article translates recent spike–receptor findings into practical assay-design principles while distinguishing biochemical evidence from physiological or clinical conclusions.
-
Sulfo-NHS-LC-Biotin: Practical Labeling Guide
2026-09-23
Sulfo-NHS-LC-Biotin labels accessible primary amines on proteins and peptides for stable detection, capture, or immobilization, including cell-surface protein biotinylation. It is suited to aqueous workflows that need irreversible labeling, but not to intracellular labeling or experiments requiring a reversible tag.
-
JAK Inhibitors and Endothelial Vascular Effects
2026-09-23
A 2025 comparative study shows that approved JAK inhibitors consistently reduce cytokine-induced endothelial IL-6, but differ in their effects on IL-8, adhesion molecules, coagulation factors, and apoptosis. The findings indicate that anti-inflammatory activity alone cannot define vascular safety and provide a practical framework for interpreting JAK inhibitor responses in inflammatory disease models.
-
Lenalidomide and DOT1L: Rewiring Myeloma Immunity
2026-09-22
Lenalidomide (CC-5013) is best understood not only as an immunomodulatory drug, but as a translational platform whose activity can be intensified by epigenetic control of innate immune signaling. This thought-leadership article connects DOT1L biology, assay design, biomarker strategy, and product selection for more rigorous multiple myeloma research.
-
Sex Differences in Angiotensin II Hypertension
2026-09-21
Xue, Pamidimukkala, and Hay used telemetry in conscious, freely moving mice to show that chronic angiotensin II produces a much larger blood-pressure increase in males than females despite similar baseline pressure. Gonadectomy, baroreflex testing, and ganglionic blockade linked this divergence to sex-dependent hormonal and sympathetic regulation, providing a useful framework for interpreting vascular and autonomic mechanisms in hypertension.
-
Arrb2–6-ketoLCA Signaling in Hepatic IRI
2026-09-21
The reference study identifies a hepatocyte Arrb2–6-ketoLCA axis that promotes M2 macrophage polarization and reduces hepatic ischemia–reperfusion injury. Its combination of clinical-sample analysis, hepatocyte-focused mouse genetics, hypoxia–reoxygenation experiments, and metabolomics provides a mechanistic framework for studying hepatocyte–macrophage communication, while leaving adrenergic drug modulation as a separate research question.
-
E-64d for Reliable Cell-Death Assays
2026-09-20
Learn how E-64d (SKU A1903) can improve interpretation of cell viability, proliferation, apoptosis, and cytotoxicity experiments by targeting intracellular cysteine proteases. This scenario-based guide covers mechanism, assay compatibility, preparation, data interpretation, and practical supplier selection.
-
Bradykinin BA5201: Practical Assay Guidance
2026-09-19
This guide explains how to handle Bradykinin (SKU BA5201) as an endothelium-dependent vasodilator peptide in vascular, permeability, smooth muscle, pain, and inflammation workflows. It focuses on product-controlled storage and fresh-solution handling; it does not establish clinical efficacy, diagnostic use, or a universal assay concentration.
-
Lenalidomide (CC-5013): A Causal Assay Framework
2026-09-18
Lenalidomide (CC-5013) is an immune system activation agent and angiogenesis inhibitor with applications across hematologic cancer models. This article presents a causal assay framework linking its established biology to new DOT1L–innate immune findings in multiple myeloma research.
-
Angiotensin (1-7): Reliable Cell Assay Workflows
2026-09-18
A scenario-based guide to using Angiotensin (1-7), SKU A1041, in viability, proliferation, cytotoxicity, and signaling experiments. It connects Mas receptor biology with practical decisions about solvent compatibility, dose selection, assay interpretation, and reagent quality control.
-
Mubritinib (TAK 165): Designing Better Cancer Assays
2026-09-17
Mubritinib (TAK 165) is best understood as a context-dependent mitochondrial complex I inhibitor rather than simply a historical HER2 agent. This guide connects its AML and PEL biology with pH-aware assay design, showing how translational researchers can improve dosing logic, controls, and interpretation.
-
Atrial Natriuretic Peptide: Assay Guide
2026-09-17
A scenario-based guide to using Atrial Natriuretic Peptide (ANP) (C49H84N20O15S), rat (SKU A1009) in viability, proliferation, and cardiovascular experiments. It addresses peptide handling, assay compatibility, interpretation, and vendor-selection criteria using documented product specifications and clearly separated workflow recommendations.
-
DMXAA (Vadimezan): Reliable Assay Design
2026-09-16
This scenario-driven guide explains how DMXAA (Vadimezan), SKU A8233, can support reproducible viability, apoptosis, cell-cycle, and endothelial assays. It connects mechanism-aware dose selection with formulation control, interpretation of assay variability, and practical product-selection criteria.
-
Gastrodin, AT1 Signaling, and Reactive Astrocytes
2026-09-16
The 2024 European Journal of Neuroscience study links microglia-derived inflammatory signaling with renin–angiotensin system remodeling, SIRT3 regulation, and reactive astrocyte phenotypes. Its use of an AT1-directed pharmacological perturbation strengthens the case for receptor-level analysis, while the cell-based design defines important limits for translation to neurological disease models.